JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2009, 58(2):60-66

Beta-blockers

J. Ďuricová*, M. Grundmann
Fakulta zdravotnických studií Ostravské univerzity, FN Ostrava, Ústav klinické farmakologie

Beta-adrenergic blockers rank among the principal drugs in the treatment of cardiovascular diseases. Their common mechanism of action is based on the ß-adrenergic receptor blockade. However, differences in pharmacokinetic and pharmacodynamic properties exist between the individual agents in the beta-blocker class, and these differences may be of clinical relevance. In addition, responses to beta-blockers are variable among patients. Genetic plymorphism in drug-metabolizing enzymes, including cytochrome P450 2D6, has been demonstrated to contribute to the variability of several beta-blockers. The understanding of beta-blocker properties and their differences is thus important for their proper clinical use.

Keywords: beta-blockers; pharmacokinetics; pharmacodynamics; P450 2D6

Received: March 23, 2009; Accepted: April 1, 2009; Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďuricová J, Grundmann M. Beta-blockers. Čes. slov. farm. 2009;58(2):60-66.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reiter M. J.: Prog Cardiovasc Dis., 2004; 47, 11-33. Go to original source... Go to PubMed...
    2. López-Sendón J., Swedberg K., McMurray J. et al.: Eur Heart J., 2004; 25, 1341-1362.
    3. O'Rourke S. T.: Am J Pharm Educ., 2007; 71, 1-6. Go to original source... Go to PubMed...
    4. Bristow M. R.: Circulation, 2000; 101, 558-569. Go to original source... Go to PubMed...
    5. Vítovec J., Špinar J.: Interní Med., 2008; 10, 126-128.
    6. Cruickshank J. M.: Circulation., 1990; 82, 60-65. Go to original source... Go to PubMed...
    7. Andrus M. R., Loyed J. V.: Drugs Aging., 2008; 25, 131-144. Go to original source... Go to PubMed...
    8. Prisant L. M.: J Clin Pharmacol., 2008; 48, 225-239. Go to original source... Go to PubMed...
    9. Souček M.: Interní Med., 2008; 2, 58-61.
    10. Keating G. M., Jarvis B.: Drugs, 2003; 63, 1697-1741. Go to original source... Go to PubMed...
    11. McDevitt D. G.: Eur Heart J., 1987; 8, 9-14. Go to original source... Go to PubMed...
    12. Riddell J. G., Harron D. W. G., Shanks R. G.: Clin Pharmacokinet., 1987; 12, 305-320. Go to original source... Go to PubMed...
    13. Mehvar R., Brocks D. R.: J Pharm Pharm Sci., 2001; 4, 185-200.
    14. Fox K., García M. A., Ardissino D. et al.: Eur Heart J., 2006; 27, 1341-1381.
    15. Bassand J. P., Hamm C. H. W., Ardissino D. et al.: Eur Heart J., 2007; 28, 1598-1660.
    16. Bělohlávek J, Aschermann M.: Cor Vasa, 2008; 50, 1S7-1S23. Go to original source...
    17. Janoušek S.: Interv Akut Kardiol., 2004; 3, 189-191.
    18. van de Werf F., Bax J., Betriu A. et al.: Eur Heart J., 2008; 29, 2909-2945. Go to original source... Go to PubMed...
    19. Gourine A., Bondar S. I., Spyer K. M. et al.: Circ Res., 2008; 102, 633-636. Go to original source... Go to PubMed...
    20. Špinar J., Hradec J., Meluzín J. et al.: Cor Vasa, 2007; 49, 5-34.
    21. Prakash A., Markham A.: Drugs, 2000; 60, 647-678. Go to original source... Go to PubMed...
    22. Dahlöf B., Sever P. S., Poulter N. R. et al.: Lancet, 2005; 366, 895-906. Go to original source... Go to PubMed...
    23. Dahlöf B., Devereux R. B., Kjeldsen S. E. et al.: Lancet, 2002; 359, 1004-1010. Go to original source... Go to PubMed...
    24. Grundmann M., Kacířová I.: Postgraduální medicína., 2007; 9, 652-660.
    25. Widimský J., Cífková R., Špinar J. et al.: Cor Vasa., 2008; 50, 5-22.
    26. Zipes D. P., Camm A. J., Borggrefe M. et al.: Europace., 2006; 8, 746-837.
    27. Blomström-Lundqvist C, Sheinman MM, Aliot EM a kol. J Am Coll Cardiol., 2003; 42: 1493-1531.
    28. Anzenbacher P., Anzenbacherová E.: CMLS Cell Mol Life Sci., 2001; 58, 737-747. Go to original source... Go to PubMed...
    29. Mičuda S., Martínková J., Chládek J. et al.: Remedia., 1998; 8, 226-236.
    30. Bernard S., Neville K. A., Nguyen A. T. et al.: Clinical Implications. Oncologist., 2006; 11, 126-135. Go to original source... Go to PubMed...
    31. Buzková H., Pechandová K., Slanař O. et al.: Prague Med Rep., 2006; 107, 383-393.
    32. Volotinen M., Turpeinen M., Tolonen A. et al.: Drug Metab Dispos., 2007; 35, 1135-1141. Go to original source... Go to PubMed...
    33. Lewis R. V., Lennard M. S., Jackson P. R. et al.: Br. J. Clin. Pharmacol., 1985; 19, 329-333. Go to original source... Go to PubMed...
    34. Lennard M. S., Lewis R. V., Brawn L. A.: Br. J. Clin. Pharmacol., 1989; 27, 429-434. Go to original source... Go to PubMed...
    35. Nieminen T., Uusitalo H., Mäenpää J. et al.: Eur. J. Clin. Pharmacol., 2005; 61, 811-819. Go to original source... Go to PubMed...
    36. Zhou H. H., Wood A. J. J.: Clin. Pharmacol. Ther., 1995; 57, 518-524. Go to original source... Go to PubMed...
    37. Ishida K., Taira S., Morishita H. et al.: Bil. Pharm. Bull., 2008; 31, 1297-1300. Go to original source... Go to PubMed...
    38. Honda M., Nozawa T., Igarashi N. et al.: Biol. Pharm. Bull., 2005; 28, 1476-1479. Go to original source... Go to PubMed...
    39. Takekuma Y., Takenaka T., Kiyokawa M. et al.: Biol. Pharm. Bull., 2007; 30, 537-542. Go to original source... Go to PubMed...
    40. Graff D. W., Williamson K. M., Pieper J. A. et al.: J. Clin. Pharmacol., 2001; 41, 97-106. Go to original source... Go to PubMed...
    41. Lefebvre J., Poirier L., Poirier P. et al.: Br. J. Clin. Pharmacol., 2006; 63, 575-582. Go to original source... Go to PubMed...
    42. Beresford R., Heel R. C.: Drugs., 1986; 31, 6-28. Go to original source... Go to PubMed...
    43. Frishman W. H., Tepper D., Lazar E. J. et al.: J. Clin. Pharmacol., 1990; 30, 686-692. Go to original source... Go to PubMed...
    44. de Groot M. J., Ackland M. J., Horne V. A. et al.: J. Med. Chem., 1999; 42, 4062-4070. Go to original source... Go to PubMed...
    45. Zateyshchikov D. A., Minushkina L. O., Brovkin A. N. et al.: Fund. Clin. Pharmacol., 2007; 21, 437-443. Go to original source... Go to PubMed...
    46. RegĆrdh C. G., Johnsson G.: Clin. Pharmacokinet., 1980; 5, 557-569. Go to original source... Go to PubMed...
    47. Peřinová I., Ďuricová J., Brozmanová H., Kacířová I., Grundmann M.: Čes. a slov. Farm., 2008; 57, 254-259.
    48. Cerqueira P. M., Cesarino E. J., Mateus F. H. et al.: Chirality., 1999; 11, 591-597. Go to original source...
    49. Ismail R., Teh L. K.: J Clin Pharm Ther., 2006; 31, 99-109. Go to original source... Go to PubMed...
    50. Koytchev R., Alken R. G., Vlahov V. et al.: Eur J Clin Pharmacol., 1998; 54, 469-474. Go to original source... Go to PubMed...
    51. Seeringer A., Brockmöller J., Bauer S. et al.: Eur J Clin Pharmacol., 2008; 64, 883-888. Go to original source... Go to PubMed...
    52. Kirchheiner J., Heesch C., Bauer S. et al.: Clin Pharmacol Ther., 2004; 76, 302-312. Go to original source... Go to PubMed...
    53. Goryachkina K., Burbello A., Boldueva S. et al.: Eur J Clin Pharmacol 2008; 64, 1163-1173. Go to original source... Go to PubMed...
    54. Bijl M. J., Visser L. E., van Schaik R. H. N. et al.: Clin Pharmacol Ther., 2009; 85, 45-50. Go to original source... Go to PubMed...
    55. Wuttke H., Rau T., Heide R. et al.: Clin Pharmacol Ther., 2002; 72, 429-437. Go to original source... Go to PubMed...
    56. Fux R., Mörike K., Pröhmer A. M. T. et al.: Clin Pharmacol Ther., 2005; 78, 378-387. Go to original source... Go to PubMed...
    57. Zineh I., Beitelshees A. L., Gaedigk A. et al.: Clin Pharmacol Ther., 2004; 76, 536-544. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.